Actively Recruiting
Study of HPK1 Inhibitor BGB-26808 Alone or with Tislelizumab and Chemotherapy in Adults with Advanced Solid Tumors
Led by BeOne Medicines · Updated on 2026-09-28
337
Participants Needed
28
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating BGB-26808, a HPK1 inhibitor, alone or combined with tislelizumab, an anti-PD-1 antibody, in adults with advanced solid tumors. This phase 1 trial aims to find the recommended dose for BGB-26808 and to assess its safety, tolerability, and preliminary antitumor effects. The study is open-label, nonrandomized in dose escalation, and later includes dose expansion phases.
CONDITIONS
Brief Title
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
Research Team
S
Study Director
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here